Stryker Acquires Arrinex

Image courtesy of Stryker.

Register to receive a free U.S. Market for ENT Devices Report Suite report synopsis and brochure

Stryker announced that it has successfully acquisitioned Arrinex, Inc. Arrinex built its following when it engineered ClariFix®, a new cryoablation technology which treats chronic rhinitis. By Stryker taking over Arrinex, Stryker’s ENT market position expands greatly, as prior to this acquisition, Stryker did not compete in the ENT market.

“The acquisition of Arrinex is highly complementary to Stryker’s ENT portfolio, which is part of our Neurotechnology business,” said Spencer Stiles, Stryker’s Group President, Neurotechnology, Instruments and Spine. “This acquisition aligns with our focus on providing ENT physicians with new technologies that deliver more treatment options and better patient outcomes.”

In 2018, the U.S. market for ENT  devices was valued at $824.5 million. The total market for ENT devices is expected to increase at moderate rate over the forecast period. However, declining ASPs in multiple segments will cause the rate of growth to gradually abate. The largest segments included the balloon sinus dilation devices, powered instruments and radiofrequency device markets. Bronchoscopy medical devices made up the remaining market value of 19.5%. Bronchoscopy is less commonly performed than ENT and thus, the market for bronchoscopic devices represents a smaller percentage of the total market.


For Further Information

More on the bronchoscope market in the U.S. can be found in a report suite published by iData Research entitled the U.S. Market for ENT Devices Report Suite.

Leave a Reply